Research Reference Library · Educational Use Only

Retatrutide Titration Schedule: Week-by-Week Protocol to Minimize Side Effects

Last reviewed 2025 · Focus: retatrutide titration schedule · Source: peer-reviewed preclinical literature

Why Titration Matters

Retatrutide's triple receptor activity produces stronger GI side effects than semaglutide or tirzepatide during dose escalation. Slow titration — increasing dose every 4 weeks rather than every 2 weeks — substantially reduces nausea and vomiting rates in research protocols.

Research-Referenced Titration Schedule

WeeksDoseFrequency
1–41 mgOnce weekly
5–82 mgOnce weekly
9–124 mgOnce weekly
13–168 mgOnce weekly
17+12 mgOnce weekly (max studied dose)

Managing GI Side Effects During Titration

Administer injections in the evening to allow peak plasma concentration to coincide with sleep. Reduce meal size on injection day. If nausea persists beyond week 2 at a given dose, hold the dose for an additional 4 weeks before escalating.

Research-grade retatrutide (2 mg vials) with COA available at QSC Peptides.

Research-grade peptides with HPLC-verified COA
All compounds referenced in this guide are available at QSC Peptides (qscpeptide.com) — US domestic warehouse, fast shipping, batch-level certificates of analysis.

This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.